Sanofi $SNY Stock Sold by Kestra Advisory Services LLC

Kestra Advisory Services LLC cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 56.4% in the third quarter, HoldingsChannel reports. The fund owned 60,459 shares of the company’s stock after selling 78,280 shares during the period. Kestra Advisory Services LLC’s holdings in Sanofi were worth $2,493,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after acquiring an additional 940,342 shares in the last quarter. Regal Partners Ltd raised its stake in Sanofi by 33.2% during the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after acquiring an additional 633,782 shares during the period. Royal Bank of Canada lifted its holdings in Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after purchasing an additional 470,882 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in Sanofi by 399.3% during the first quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock valued at $15,270,000 after purchasing an additional 253,465 shares in the last quarter. Finally, Mondrian Investment Partners LTD lifted its holdings in Sanofi by 2.3% during the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after purchasing an additional 129,575 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SNY shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. HSBC restated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Wolfe Research assumed coverage on shares of Sanofi in a research note on Friday, October 9th. They set a “peer perform” rating on the stock. Royal Bank Of Canada initiated coverage on shares of Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Finally, Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Check Out Our Latest Stock Analysis on SNY

Sanofi Price Performance

SNY stock opened at $48.37 on Monday. Sanofi has a one year low of $39.07 and a one year high of $52.67. The company’s fifty day moving average price is $42.68 and its 200-day moving average price is $44.38. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.27 and a current ratio of 1.12. The company has a market capitalization of $117.27 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.32 and a beta of 0.31.

Sanofi (NASDAQ:SNY – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. Sanofi’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.91 earnings per share. On average, equities analysts anticipate that Sanofi will post 5.07 EPS for the current fiscal year.

About Sanofi

(Free Report)

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

Further Reading

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.